Venrock Healthcare Capital Par Purchases 100,000 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par bought 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 12th. The stock was purchased at an average price of $9.23 per share, for a total transaction of $923,000.00. Following the transaction, the insider now owns 5,217,285 shares of the company’s stock, valued at $48,155,540.55. The trade was a 1.95 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Monday, February 10th, Venrock Healthcare Capital Par bought 4,137 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average price of $9.14 per share, for a total transaction of $37,812.18.
• On Friday, February 7th, Venrock Healthcare Capital Par bought 73,649 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average price of $9.29 per share, for a total transaction of $684,199.21.
• On Monday, February 3rd, Venrock Healthcare Capital Par acquired 14,562 shares of KalVista Pharmaceuticals stock. The stock was bought at an average price of $9.22 per share, for a total transaction of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par acquired 43,707 shares of KalVista Pharmaceuticals stock. The stock was bought at an average price of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Price Performance

Shares of KALV stock opened at $9.76 on Friday. The company has a market cap of $482.32 million, a price-to-earnings ratio of -2.68 and a beta of 0.85. The stock has a 50 day simple moving average of $8.75 and a 200-day simple moving average of $10.54. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.01. Analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Suvretta Capital Management LLC raised its stake in KalVista Pharmaceuticals by 0.5% in the 3rd quarter. Suvretta Capital Management LLC now owns 4,212,005 shares of the specialty pharmaceutical company’s stock valued at $48,775,000 after purchasing an additional 20,000 shares during the last quarter. Vestal Point Capital LP raised its stake in KalVista Pharmaceuticals by 73.9% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after purchasing an additional 1,700,000 shares during the last quarter. Vanguard Group Inc. raised its stake in KalVista Pharmaceuticals by 4.9% in the 4th quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company’s stock valued at $19,102,000 after purchasing an additional 104,716 shares during the last quarter. Boxer Capital Management LLC acquired a new position in KalVista Pharmaceuticals in the 4th quarter valued at $13,467,000. Finally, State Street Corp raised its stake in KalVista Pharmaceuticals by 68.1% in the 3rd quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after purchasing an additional 515,179 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on KALV shares. Bank of America started coverage on KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price objective on the stock. JMP Securities started coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price objective on the stock. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Finally, TD Cowen assumed coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $23.80.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).